One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
September 21 2007 - 9:00AM
PR Newswire (US)
-- When compared to insulin glargine, exenatide offered added
benefits of weight loss and improved beta-cell function when used
with metformin -- AMSTERDAM, Netherlands, Sept. 21
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) today announced
study results comparing treatment of exenatide injection with
insulin glargine on beta-cell function, glycemic control and weight
in people with type 2 diabetes. Study findings showed one year of
exenatide therapy, as compared to insulin glargine, markedly
improved different indices of beta-cell function, along with
similar glycemic improvement. In addition, patients treated with
exenatide lost weight, whereas patients treated with glargine
gained weight. These findings were presented at the 43rd Annual
Meeting of the European Association for the Study of Diabetes
(EASD) in Amsterdam, The Netherlands(1). In this randomized study,
69 people with type 2 diabetes who were treated with exenatide (5
mcg BID for 4 weeks and 10 mcg BID to 20 mcg TID (20 mcg TID is a
currently unapproved dosage of the marketed formulation of
exenatide, BYETTA(R) (exenatide) injection) for the remainder of
the year) or insulin glargine (both with metformin) were compared
on measures of beta-cell function, blood sugar control and weight
change after one year (52-weeks) of treatment. In this study,
people with type 2 diabetes who used exenatide for one year,
compared to those treated with insulin glargine, showed significant
improvements in beta-cell function as measured by arginine and
glucose induced C-peptide (a peptide associated with insulin
production) secretion during a glucose clamp procedure (a technique
used to assess insulin secretion)(2,3). Specifically, C-peptide
secretion in response to arginine administration (which produces
maximal beta-cell stimulation) was 146 percent greater after one
year of treatment with exenatide when compared to insulin glargine
(mean ratio relative to baseline for exenatide and insulin glargine
+ or -SEM: 3.19 + or - 0.24 vs. 1.31 + or - 0.07, respectively, p
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024